A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients

  1. Zhanwei Du
  2. Lin Wang
  3. Yuan Bai
  4. Yunhu Liu
  5. Eric HY Lau
  6. Alison P Galvani
  7. Robert M Krug
  8. Benjamin John Cowling  Is a corresponding author
  9. Lauren A Meyers  Is a corresponding author
  1. University of Hong Kong, Hong Kong
  2. University of Cambridge, United Kingdom
  3. Yale University, United States
  4. The University of Texas at Austin, United States
  5. University of Hong Kong, China

Abstract

Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients. By fitting a mathematical model of within-host Omicron viral dynamics to electronic health records data from 208 hospitalized patients in Hong Kong, we estimate that Paxlovid can inhibit over 90% of viral replication. However, its effectiveness critically depends on the timing of treatment. If treatment is initiated three days after symptoms first appear, we estimate a 17% chance of a post-treatment viral rebound and a 12% (95% CI: 0%-16%) reduction in overall infectiousness for non-rebound cases. Earlier treatment significantly elevates the risk of rebound without further reducing infectiousness, whereas starting beyond five days reduces its efficacy in curbing peak viral shedding. Among the 104 patients who received Paxlovid, 62% began treatment within an optimal three-to-five-day day window after symptoms appeared. Our findings indicate that broader global access to Paxlovid, coupled with appropriately timed treatment, can mitigate the severity and transmission of SARS-Cov-2.

Data availability

All data used in this study can be accessed through Github: https://github.com/ZhanweiDU/PaxHK/.

Article and author information

Author details

  1. Zhanwei Du

    Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2020-767X
  2. Lin Wang

    Department of Genetics, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5371-2138
  3. Yuan Bai

    Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
    Competing interests
    No competing interests declared.
  4. Yunhu Liu

    Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
    Competing interests
    No competing interests declared.
  5. Eric HY Lau

    Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
    Competing interests
    No competing interests declared.
  6. Alison P Galvani

    Center for Infectious Disease Modeling and Analysis, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  7. Robert M Krug

    Department of Molecular Biosciences, The University of Texas at Austin, Austin, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3754-5034
  8. Benjamin John Cowling

    Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
    For correspondence
    bcowling@hku.hk
    Competing interests
    Benjamin John Cowling, reports honoraria from AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer,Sanofi Pasteur, and Roche. The authors report no other potential conflicts of interest.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6297-7154
  9. Lauren A Meyers

    Department of Integrative Biology, The University of Texas at Austin, Austin, United States
    For correspondence
    laurenmeyers@austin.utexas.edu
    Competing interests
    No competing interests declared.

Funding

Innovation and Technology Commission (AIR@InnoHK)

  • Zhanwei Du

Health and Medical Research Fund (07210147)

  • Zhanwei Du

National Natural Science Foundation of China (82304204)

  • Yuan Bai

National Institutes of Health (AI151176)

  • Lauren A Meyers

Centers for Disease Control and Prevention (U01IP001136)

  • Lauren A Meyers

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. James M McCaw, University of Melbourne, Australia

Ethics

Human subjects: Individual patient-informed consent was not required in this study using anonymized data.

Version history

  1. Received: May 31, 2023
  2. Accepted: April 3, 2024
  3. Accepted Manuscript published: April 16, 2024 (version 1)
  4. Version of Record published: May 8, 2024 (version 2)

Copyright

© 2024, Du et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 961
    views
  • 188
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zhanwei Du
  2. Lin Wang
  3. Yuan Bai
  4. Yunhu Liu
  5. Eric HY Lau
  6. Alison P Galvani
  7. Robert M Krug
  8. Benjamin John Cowling
  9. Lauren A Meyers
(2024)
A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
eLife 13:e89801.
https://doi.org/10.7554/eLife.89801

Share this article

https://doi.org/10.7554/eLife.89801

Further reading

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Patrick E Brown, Sze Hang Fu ... Ab-C Study Collaborators
    Research Article

    Background: Few national-level studies have evaluated the impact of 'hybrid' immunity (vaccination coupled with recovery from infection) from the Omicron variants of SARS-CoV-2.

    Methods: From May 2020 to December 2022, we conducted serial assessments (each of ~4000-9000 adults) examining SARS-CoV-2 antibodies within a mostly representative Canadian cohort drawn from a national online polling platform. Adults, most of whom were vaccinated, reported viral test-confirmed infections and mailed self-collected dried blood spots to a central lab. Samples underwent highly sensitive and specific antibody assays to spike and nucleocapsid protein antigens, the latter triggered only by infection. We estimated cumulative SARS-CoV-2 incidence prior to the Omicron period and during the BA.1/1.1 and BA.2/5 waves. We assessed changes in antibody levels and in age-specific active immunity levels.

    Results: Spike levels were higher in infected than in uninfected adults, regardless of vaccination doses. Among adults vaccinated at least thrice and infected more than six months earlier, spike levels fell notably and continuously for the nine months post-vaccination. By contrast, among adults infected within six months, spike levels declined gradually. Declines were similar by sex, age group, and ethnicity. Recent vaccination attenuated declines in spike levels from older infections. In a convenience sample, spike antibody and cellular responses were correlated. Near the end of 2022, about 35% of adults above age 60 had their last vaccine dose more than six months ago, and about 25% remained uninfected. The cumulative incidence of SARS-CoV-2 infection rose from 13% (95% CI 11-14%) before omicron to 78% (76-80%) by December 2022, equating to 25 million infected adults cumulatively. However, the COVID-19 weekly death rate during the BA.2/5 waves was less than half of that during the BA.1/1.1 wave, implying a protective role for hybrid immunity.

    Conclusions: Strategies to maintain population-level hybrid immunity require up-to-date vaccination coverage, including among those recovering from infection. Population-based, self-collected dried blood spots are a practicable biological surveillance platform.

    Funding: Funding was provided by the COVID-19 Immunity Task Force, Canadian Institutes of Health Research, Pfizer Global Medical Grants, and St. Michael's Hospital Foundation. PJ and ACG are funded by the Canada Research Chairs Program.

    1. Computational and Systems Biology
    2. Epidemiology and Global Health
    Javier I Ottaviani, Virag Sagi-Kiss ... Gunter GC Kuhnle
    Research Article

    The chemical composition of foods is complex, variable, and dependent on many factors. This has a major impact on nutrition research as it foundationally affects our ability to adequately assess the actual intake of nutrients and other compounds. In spite of this, accurate data on nutrient intake are key for investigating the associations and causal relationships between intake, health, and disease risk at the service of developing evidence-based dietary guidance that enables improvements in population health. Here, we exemplify the importance of this challenge by investigating the impact of food content variability on nutrition research using three bioactives as model: flavan-3-ols, (–)-epicatechin, and nitrate. Our results show that common approaches aimed at addressing the high compositional variability of even the same foods impede the accurate assessment of nutrient intake generally. This suggests that the results of many nutrition studies using food composition data are potentially unreliable and carry greater limitations than commonly appreciated, consequently resulting in dietary recommendations with significant limitations and unreliable impact on public health. Thus, current challenges related to nutrient intake assessments need to be addressed and mitigated by the development of improved dietary assessment methods involving the use of nutritional biomarkers.